M. Cherry

发表

Finding protein kinase hits using structural information.

J. Reader, M. Cherry, David Williams, 2006, Progress in medicinal chemistry.

Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights.

D. Williams, M. Cherry, 2004, Current medicinal chemistry.

Introduction to Fragment‐Based Drug Discovery

Mike Cherry, Tim Mitchell, M. Cherry, 2008 .

Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

Ian Collins, C. E. Allen, Michelle D Garrett, 2010, Bioorganic & medicinal chemistry letters.

1 Introduction to Fragment-based Drug Discovery

M. Cherry, T. Mitchell, 2008 .

Transition metal molecular glasses by design: mexylaminotriazine-functionalized salicylaldehyde imine ligands

M. Cherry, O. Lebel, M. Jokar, 2019, New Journal of Chemistry.

Symmetrical, unsymmetrical and bridged calix[4]arene derivatives as neutral carrier ionophores in poly (vinyl chloride) membrane sodium selective electrodes.

S. Harris, M. Cherry, K. O'Connor, 1994, Talanta.

The effects of fuel-to-oxidizer ratio on luminescence properties and particle morphology of combustion-synthesized europium-activated barium magnesium aluminate

J. Mourant, J. McKittrick, G. Hirata, 2000 .

Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks◆

P. Eyers, M. Chu, C. Bignell, 2009, The Journal of Biological Chemistry.

Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes.

L. Tabernero, P. Eyers, M. Chu, 2010, Biochemistry.

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Gary Box, Ian Collins, Isaac M. Westwood, 2011, Journal of medicinal chemistry.

Identification of inhibitors of checkpoint kinase 1 through template screening.

Ian Collins, Samantha Burns, David Williams, 2009, Journal of medicinal chemistry.

Fragment-Based Drug Design Fragments offer the prospect of a more efficient approach to drug discovery - resulting in the generation of high-quality leads with a better chance of success in clinical development.

Mike Cherry, Tim Mitchell, Sareum Ltd, 2005 .